Caspofungin versus liposomal amphotericin B: are they really comparable?
Sekine
Leo
L
Humbwavali
João
J
Wolff
Fernando Herz
FH
Barcellos
Nêmora Tregnago
NT
D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D054714:Echinocandins / Q000009:adverse effects / Q000627:therapeutic use*; D005335:Fever of Unknown Origin / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D055666:Lipopeptides; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin